Mosaic Therapeutics appoints Dr Stephen Shuttleworth as Chief Scientific Officer
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced the appointment of Dr Stephen Shuttleworth as Chief Scientific Officer (CSO).
